The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).
Franco Cavalli
No relevant relationships to disclose
Brendan Rooney
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Lixia Pei
Employment or Leadership Position - Janssen Research & Development
Helgi Van De Velde
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Tadeusz Robak
Consultant or Advisory Role - Johnson & Johnson (U); Roche (U)
Research Funding - Johnson & Johnson; Roche